Sotac Pharmaceuticals Limited

As of March 31, 2025, Sotac Pharmaceuticals Limited carries a market capitalization of 1.31B, placing it among publicly traded companies globally. Its enterprise value stands at 1.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Sotac Pharmaceuticals Limited has 11.05M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Sotac Pharmaceuticals Limited maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, Sotac Pharmaceuticals Limited recorded an income tax benefit of -4.56M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 21, 2026, Sotac Pharmaceuticals Limited's stock has declined approximately 26.40% over the past 52 weeks. The 50-day moving average sits at 106.30, while the 200-day moving average is 117.06.

As of March 31, 2025, Sotac Pharmaceuticals Limited holds 17.96M in cash and equivalents against 436.99M in total debt, resulting in a net debt position of 421.35M. Total book value stands at 532.52M, with working capital of 182.78M providing operational flexibility.